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Key messages
 ► Novel method of collecting data in this field—
continuously in daily life through a mobile phone 
application.
 ► Investigating previously poorly understood areas of 
the experience and recall of breathlessness.
 ► Multidimensional approach to breathlessness.
 ► Easy to expand or modify study procedure for use in 
other settings.
 ► One limitation might be the low level of control of 
included participants in the general cohort.
ABSTRACT
Background Breathlessness, the subjective sensation 
of breathing discomfort, is common and appears in 
the daily life of people with cardiorespiratory diseases. 
Physicians often rely on patient’s history based on 
symptom recall. The relation between recalled and 
experienced breathlessness is still poorly understood. 
This paper presents the protocol for a study primarily 
aimed at evaluating the relationship between experienced 
breathlessness and (1) recalled breathlessness and (2) 
predicted future breathlessness.
Methods A mobile phone application will be used to 
collect data during daily life. Medically stable participants, 
≥18 years of age with mean daily breathlessness of 
Numerical Rating Scale (NRS) 3/10 and able to use a 
mobile phone with internet will rate their breathlessness 
intensity on a 0–10 NRS prompted the user several 
times daily for 1 week. Participants will recall their 
breathlessness each day and week. Multivariable random 
effects regression models will be used for statistical 
analyses.
Results Results of the study will be submitted for 
publication in peer-reviewed journals and presented at 
relevant conferences.
Discussion This protocol describes a study aimed at 
investigating previously unknown areas of the experience 
and recall of breathlessness using a new method of data 
collection.
Registration details Prospectively registered with  
ClinicalTrials. gov (Nr: NCT03468205).
Ethics and dissemination The study has received ethical 
approval from the Regional Ethical Review Board Lund 
(DNr 2017/149). After a general study information including 
that participation is entirely voluntary, participants will 
answer the eligibility criteria and be asked to consent to 
participate before entering the study questions. Written 
informed consent to participate will be obtained for 
participants in the clinical sub-cohort. Participation can be 
discontinued at the discretion of the participant in which 
case no further data will be collected.
InTRoDuCTIon
Breathlessness, the subjective sensation of 
breathing discomfort, is common and appears 
with varying severity in daily life of people 
across several diseases such as congestive 
heart failure, asthma and chronic obstructive 
pulmonary disease (COPD).1–3 Breathlessness 
affects nearly a quarter of people aged over 60 
years and about half of patients with serious 
illness.1–3 It is associated with increased anxiety 
and depression, increased risk of hospitalisa-
tion and earlier death.4 5 Several qualitatively 
distinct sensations of varying intensity consti-
tute breathlessness making it a multidimen-
sional symptom. These dimensions include the 
experienced intensity and unpleasantness, the 
associated emotional response and the func-
tional impact on the person’s life.6
Clinical care relies on the patient’s history 
based on his/her symptom recall. The recalled 
level of recent breathlessness is used by the 
health professional to decide on the need for 
further investigations and treatment. Studies 
have shown that the recalled intensity of breath-
lessness during laboratory-provoked symptoms 
is not the same as the symptom actually expe-
rienced in daily life.7 This mismatch has also 
been shown for other measures for pain or 
self-perceived happiness.8 Further, previous 
studies show poor communication about 
breathlessness between doctors and patients, 
and ratings performed by healthcare profes-
sionals and caregivers of the patient’s symptom 
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Box 1 Research questions
Three types of breathlessness measures evaluated: experienced 
(at a time point), recalled (remembered) and predicted (future) 
breathlessness. The main research questions are:
1 How is the recalled breathlessness intensity for a time 
period (T1) related to:
1.1 Experienced breathlessness intensity during T1 measured as:
1.1a Mean experienced intensity?
1.1b Peak experienced intensity?
1.1c Most recent experienced intensity?
1.1d Perceived self-efficacy related to the breathlessness?
1.1e Personality trait of high symptom sensitivity at baseline?
1.2 Predicted breathlessness intensity for a future time period (T2)?
2 How is the predicted breathlessness intensity for a 
subsequent time period (T2) related to:
2.1 Experienced breathlessness intensity during T1?
2.2 Recalled breathlessness intensity during T1?
2.3 Experienced breathlessness intensity during T2?
3 Which factors are associated with the difference score between:
3.1 Experienced and recalled breathlessness intensity during T1?
3.2 Predicted and experienced breathlessness intensity during T2?
severity often do not match. This problem increased with 
higher levels of symptoms.9 Lack of communication and 
understanding of the patient’s symptoms lead to poor 
concordance, inappropriate treatment decisions and influ-
ence the patients adherence with treatment.9–11 The gold 
standard for assessing the symptom severity is currently 
patient recall.
Several factors may influence the recalled symptom 
intensity including the highest and the final experienced 
intensity.12 13 This association is often referred to as the 
‘peak-end rule’ and has been found to be important for 
the overall recall of pain and happiness.12 13 Studies evalu-
ating the ‘peak-end rule’ in breathlessness have previously 
shown contradictory results between groups.14 The current 
intensity of breathlessness is the measure shown to be the 
most associated with the recalled intensity.15 Additionally, 
even a very small decline in cognitive status influenced the 
differences between recalled and experienced symptoms, 
giving a bigger difference and increased variance between 
actual and recalled symptoms.15
No previous studies exist on how patients own predic-
tions of future breathlessness influence the actual and 
recalled breathlessness. The hypothesis that patients own 
predictions may influence the actual intensity of breathless-
ness will be tested in this study.
This paper presents the protocol for a study of the 
relationship between experienced and recalled breath-
lessness with contemporaneous data collected using a 
mobile phone application. Through this, new information 
will be gathered on which factors that influence patients 
recall of breathlessness which is the foundation of several 
important clinical decisions regarding treatment and eval-
uations. Better understanding of these issues may thus have 
a big impact in the daily interactions between breathless 
individuals and their doctors. Specific research questions 
are presented in box 1.
AIMS
The primary aim is to evaluate the relationship between 
experienced breathlessness and (1) recalled breathlessness 
and (2) predicted future breathlessness. Secondary aims 
are to identify factors that influence the difference between 
experienced and recalled or predicted breathlessness, to 
evaluate how people think when they recall breathlessness 
over defined time periods and to evaluate a novel method 
of collecting data in this field. (box 1)
METHoDS AnD AnAlySIS
Study design and population
Inclusion criteria are age ≥18 years with a self-reported 
breathlessness intensity ≥3 on a 0–10 Numerical Rating 
Scale (NRS) during the prior 2 weeks not caused by an 
acute infection such as an upper respiratory tract infec-
tion or pneumonia. Participants should be clinically stable 
without expected need for hospital admission within 1 
week, be able to walk without a personal aid (rollator 
allowed), be able to use a device (smartphone/pad) with 
internet access regularly and be able to read and complete 
baseline assessments. The default setting is 1 week of partic-
ipation, but there is a possibility to continue for additional 
weeks at the discretion of the participant. Participants will 
be recruited into two different cohorts, one general cohort 
which include most participants and one smaller clinical 
subcohort study with fewer participants but with added 
data.
Recruitment
Potential participants will be identified by clinical and 
research staff at the centres of the participating investiga-
tors including primary care, pulmonary clinics and internal 
medicine/cardiology departments in Blekinge, Örebro and 
Skane University Hospitals (Lund/Malmö). Participants 
will also be recruited through advertisements in national 
and local newspapers and magazines including those of the 
Swedish Respiratory Society, the Swedish Heart-Lung Foun-
dation and the Heart-Lung Association and on webportals/
sites.
Mobile phone application-based data collection
The mobile phone application is available on the two 
major mobile platforms in the market today (iOS and 
Android) and can be downloaded for free through their 
respective distribution channels (ie, ‘App Store’ for Apple 
and ‘Google Play’ for Android) and installed directly on 
the participants’ personal mobile phones. It was developed 
by the company ‘Cybercom group’ in close collabora-
tion with the authors of this article and tested repeatedly 
for functionality in pilot-testing by authors and a small 
group of healthy volunteers. To access and start the active 
survey a four-digit code is needed which is distributed to 
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Figure 1 Overview of the timing of planned assessments, starting with eligibility, consent and baseline assessments 
then continuing with several daily prompts asking on intensity of breathlessness as well as morning, evening and weekly 
assessments including daily recall and daily predictions as well as a weekly recall.
participants by research staff or through the advertising. 
Baseline data will be recorded when starting the applica-
tion and individual daily start and stop times will be set. 
At regular intervals during each day, the application will 
cue the participant, using sound and homepage notifica-
tions, to self-rate the intensity of breathlessness during the 
last 10–15 min. Each cue can be ignored or filled in later. 
Recall of breathlessness during the preceding night or day 
and additional measurements are rated in the application 
each morning and, for the whole week at the end of each 
week in the study (figure 1). The participant can quit the 
application at any time and will be asked to complete the 
cessation/exit assessments for the completed part of that 
week. If any problems or questions arise during the study 
period, there is a help section within the application with 
an email address to the primary investigators. All appli-
cation data, linked to the participant-specific study ID, is 
encrypted and transferred to a central database in real time 
via the internet connection. If no internet connection is 
available at the time of transfer or if for some reason the 
data transfer is interrupted, the data will be stored locally 
on the device and the application will try to resend when 
the connection is re-established and stabilised. The data 
will also be kept on the device until the end of the study as 
a safeguard to create a redundancy.
Clinical substudy
A subset of participants at the study centres will be asked 
to participate in a clinical substudy. In addition to the 
information regarding the main application-based study, 
these participants will receive specific information about 
the substudy on paper and be asked to give their written 
informed consent to participate. Data including demo-
graphics, diagnoses, measures of pulmonary and cardiac 
function, treatments and hospitalisations will be obtained 
from medical records and national registries with up 
to 5 years follow-up of diagnoses and hospitalisations 
(Patient Registry), dispensed medications (Prescribed 
Drug Registry) and survival (Causes of Death Registry). 
Participants in the clinical substudy will be assessed for 
cognitive impairment at the beginning of the study. Some 
participants will also be invited to take part in a semistruc-
tured qualitative interview focusing on their experience of 
breathlessness and specifically how they cognitively recall 
breathlessness over different time periods such as ‘now’, 
‘last 24 hours’ or ‘last week’. This group of participants 
will also be interviewed shortly about their experiences on 
using the mobile application. A separate study protocol 
and analysis plan will be developed before starting the qual-
itative substudy.
Assessments
All planned assessments and scales within the application 
are presented in table 1. Some modifications and new ques-
tionnaires were adapted.
Breathlessness will be assessed using cued questions 
several times each day asking, ‘How intensive has your 
breathlessness been in the past 10–15 min?’, rated between 
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Table 1 Overview of the questionnaires and scales used
Item
Start of 
study
Start of 
each day
Up to every 
1–2 waking 
hours)
End of 
day
End of 
week*
End of 
study*
Main application-base study 
Age, sex X
Weight and height X
Self-reported level of mobility (Grimby-Frändin)24 X
Physician-diagnosed diseases (according to participant) X
Smoking status (never, past, current smoking) X
Modified personality trait of symptom sensitivity (PHQ-15)16 X
Mental state (anxiety/depression) (0–10 NRS) X X X
Self-perceived overall well-being (0–10 NRS) X X X
Self-efficacy regarding breathlessness (online supplementary 
appendix 1c)
X X X X
Breathlessness (0–10 NRS)
Modified Medical Research Council25–28 X X
Intensity during the previous night (0–10 NRS) X
Intensity ‘last 10–15 min’ (0–10 NRS) X X
Intensity during the time period (0–10 NRS) X X
Unpleasantness of breathlessness and intensity of descriptors of 
breathlessness (MDP)6 29
X X X X
Emotional responses related to breathlessness during the time period 
(MDP)6 29
X X X
Intensity during the past week (0–10 NRS) X X X
Predicted intensity for the coming week (0–10 NRS) X
Predicted intensity for the coming day (0–10 NRS) X X X
Previous technology and Internet experience and usage (online 
supplementary appendix 1a)
X
User experience of the application used in the trial (online 
supplementary appendix 1b)
X
MDP, multidimensional dyspnoea profile; NRS, Numerical Rating Scale; PHQ, Patient Health Questionnaire.
0 (no breathlessness) and 10 (worst imaginable breath-
lessness). The same type of assessment will be cued each 
morning (‘How intensive has your breathlessness been 
during the past night?’) and evening (‘How intensive has 
your breathlessness been during this day?’), as well as for 
the whole week (‘How intensive has your breathlessness 
been during the past week?’). The user will also be asked 
to predict, using a similar 0–10 NRS scale, how the intensity 
of breathlessness will be during the coming day, night or 
week using the question ‘How intensive do you expect your 
breathlessness to be in the coming day/night/week?’.
The Patient Health Questionnaire (PHQ) is a self-admin-
istered version of the Primary Care Evaluation of Mental 
Disorders diagnostic instrument for common mental 
disorders which are in the public domain and free to use 
in research. The PHQ-15 comprises 15 somatic symptoms 
from the PHQ, each symptom scored from 0 (‘not both-
ered at all’) to 2 (‘bothered a lot’).16 A minor modification 
was made in this study by removing one question (pain 
or problems during sexual intercourse) as the question, 
during pilot testing, was not deemed to be fully appropriate 
to ask in this format. The total score of PHQ-15 will be 
recalculated due to having one question missing in accor-
dance to the instructions from the American Psychiatric 
Association.17
To assess the self-efficacy of breathlessness, an NRS will 
be used with the question ‘How confident are you that you 
can manage breathing difficulty or avoid breathing diffi-
culty during the day’ anchored at 0 (Not at all confident) 
and 10 (Very confident).
Before and after the main study, the user will be asked 
some general questions concerning technical knowledge 
and previous experience on using a smartphone (online 
supplementary appendix 1a). After the study, some ques-
tions will be asked to evaluate the user’s experiences on 
using the application (online supplementary appendix 
1b).
For the participants in the clinical substudy, Montreal 
Cognitive Assessment Tool (MoCA) will be used to assess for 
cognitive impairment.18 19 MoCA is a brief and sensitive test 
for cognitive impairment, assessing visuospatial and execu-
tive functions, verbal ability, episodic memory, orientation 
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and attention.19 It has been validated in numerous diseases, 
including cognitive impairment related to dyspnoea, 
COPD and heart failure.20–22
Power and sample size
To obtain a power of 80% to detect a clinically and 
statistically significant difference of 1 point on a 0–10 
NRS between the mean experienced and the recalled 
daily breathlessness score, assuming a pooled SD of 
1.81 points, a minimum of 30 participants need to be 
included into the main study. This is consistent with the 
sample size of Meek et al.15 To account for loss of data 
and ensure adequate power, at least 45 participants with 
data for at least 2 days will be included prior to analysis 
of the primary research question. The data collection will 
continue even after this sample size is reached in order to 
answer also secondary research questions. Specific statis-
tical analysis plans will be developed for each objective.
Statistical analyses
Baseline characteristics will be tabulated using standard 
descriptive statistics. Mean, peak and end values of 
experienced, recalled and predicted breathlessness will 
be graphed and cross-tabulated. Associations between 
experienced, recalled and predicted breathlessness will 
be analysed using a mixed model repeated measures 
approach. Predictors of the difference score between 
recalled and experienced breathlessness, and between 
predicted and subsequently experienced breathlessness, 
respectively, will be analysed using multilevel mixed 
effects linear regression. Models will then be adjusted 
for potential confounders including age, sex, body mass 
index, level of anxiety, depression and functional status. 
The choice of an appropriate covariance structure will be 
evaluated.
The minimal clinically important difference score is 
defined as a 0.5 (small) and 1.0 (moderate/large) change 
in NRS score.23 The percentage of difference scores ≥0.5 
and ≥1.0 points will be calculated.
Statistical significance will be defined as a two-sided p 
value of <0.05.
Confidentiality
In the application, data are de-identified using a study ID 
number. For patients who do not participate in the clin-
ical substudy, the Swedish social security number is not 
recorded. For patients in the clinical substudy, clinical 
data will be cross-linked with data collected through the 
application using a key between the study ID (used in the 
application) and the participant’s Swedish social security 
number stored securely at the clinical centre.
The database used for the unidentified clinical data 
is located physically at Blekinge Institute of Technology 
and is used for several other clinical studies including 
the Swedish National Study of Ageing and Care (http:// 
ltblekinge. se/ snac) following all relevant protocols for 
data security and integrity. The code key containing the 
identifier are kept in a locked cupboard on a computer/
USB memory not connected to the Internet.
Dissemination
Data will be presented on the group level only, ensuring 
that individual participants cannot be identified. The 
findings will be published in national and international 
peer-reviewed scientific journals and presented on rele-
vant scientific conferences. The de-identified data will be 
posted in an open access data repository in accordance 
with the requirements of the scientific journal. Planned 
future papers will be concerning main and secondary 
endpoints as well as qualitative analyses on breathlessness 
measurements.
Authorship will be determined in accordance with 
the International Committee of Medical Journal Editors 
guidelines.
DISCuSSIon
This protocol describes a study aimed at investigating 
previously unknown areas of the experience and recall 
of breathlessness. This study also uses and evaluates a 
novel way of data collection which could prove to have 
numerous other applications in other research fields as 
well as in the current one. A potential limitation of this 
study is that there will be a low level of control over partic-
ipants included into the general cohort. This will be regu-
lated by giving out the four-digit code, which is needed to 
start the application, only to a selected population where 
breathlessness is anticipated to be highly prevalent. The 
Relating Experienced To Recalled breathlessness Obser-
vational study will answer several important questions 
such as the impacts and covariates of a breathless patients’ 
symptom recall. This issue has not been addressed previ-
ously and knowledge from this study could be used both 
clinically (to better understand patients) and in research 
(to better evaluate participants’ breathlessness reports). 
This study will further use the multidimensional dysp-
noea profile in the assessments and analyses of breath-
lessness recall and experience which have not previously 
been used.
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